MARKET

ANIP

ANIP

ANI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.33
+1.08
+3.82%
After Hours: 29.33 0 0.00% 16:00 12/04 EST
OPEN
28.24
PREV CLOSE
28.25
HIGH
29.48
LOW
28.24
VOLUME
38.36K
TURNOVER
--
52 WEEK HIGH
68.19
52 WEEK LOW
23.55
MARKET CAP
362.47M
P/E (TTM)
-14.8094
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is ANI Pharmaceuticals (ANIP) A Good Stock To Buy Now?
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors’ consensus returns have been exceptional. In the following paragraphs, we find out […]
Insider Monkey · 1d ago
Should Value Investors Pick ANI Pharmaceuticals (ANIP) Now?
Let's see if ANI Pharmaceuticals (ANIP) stock is a good choice for value-oriented investors right now from multiple angles.
Zacks · 11/17 15:32
ANI Pharmaceuticals EPS beats by $0.09, beats on revenue
ANI Pharmaceuticals (ANIP): Q3 Non-GAAP EPS of $0.97 beats by $0.09; GAAP EPS of $0.04 beats by $0.14.Revenue of $52.98M (+3.2% Y/Y) beats by $1.48M.Press Release
Seekingalpha · 11/05 11:56
ANI Pharmaceuticals Reports Third Quarter 2020 Results
--- Third quarter adjusted non-GAAP EBITDA of $17.0 million and adjusted non-GAAP diluted eps of $0.97 -
BusinessWire · 11/05 08:50
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter 2020 Financial Results
ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ: ANIP) today announced that the Company will release its third quarter 2020 financial results on Thursday, November 5, 2020, before the opening of the U.S. financial markets.
BusinessWire · 10/29 07:50
ANI Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that the Compensation Committee of ANI’s Board of Directors granted a non-qualified inducement stock option to purchase an aggregate of 179,643 shares of ANI’s common stock to Nikhil Lalwani, President
Business Wire · 09/11 00:00
ANI Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that the Compensation Committee of ANI's Board of Directors granted a non-qualified inducement stock option to purchase an aggregate of 179,643 shares of ANI's common stock to Nikhil Lalwani, President and Chief Executive Officer of ANI, effective September 8, 2020.
BusinessWire · 09/10 23:00
ANI Pharmaceuticals (ANIP) Q2 Earnings Miss Estimates
ANI (ANIP) delivered earnings and revenue surprises of -2.82% and 6.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 12:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANIP. Analyze the recent business situations of ANI Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANIP stock price target is 38.33 with a high estimate of 45.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 250
Institutional Holdings: 8.73M
% Owned: 70.68%
Shares Outstanding: 12.36M
TypeInstitutionsShares
Increased
43
547.29K
New
39
-289.33K
Decreased
37
430.43K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.23%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Director
Patrick Walsh
President/Chief Executive Officer/Director
Nikhil Lalwani
Chief Financial Officer/Vice President - Finance
Stephen Carey
Senior Vice President/Director of Sales
Robert Schrepfer
Senior Vice President
James Marken
Independent Director
Robert Brown
Independent Director
Thomas Haughey
Independent Director
David Nash
Independent Director
Thomas Penn
Independent Director
Antonio Pera
Independent Director
Jeanne Thoma
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ANIP
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ANI Pharmaceuticals Inc stock information, including NASDAQ:ANIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIP stock methods without spending real money on the virtual paper trading platform.